AMRN — AMARIN CORP PLC\UK
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 897448 ·
Ireland
Last close
$11.27
Market Cap
$473.82M
52W High
$17.31
52W Low
$11.15
ADV30
76,983
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 39,550,000 | 16,181,000 | -2,360,000 | 245,000 | 634,081,000 | 156,512,000 | 189,669,000 |
| Jun 2026 | 42,211,000 | 14,989,000 | -11,970,000 | -7,650,000 | 624,363,000 | 143,558,000 | 180,747,000 |
| Mar 2026 | 45,132,000 | 17,769,000 | -8,011,000 | -10,512,000 | 645,764,000 | 131,063,000 | 196,351,000 |
| Dec 2025 | 49,219,000 | 23,169,000 | -2,261,000 | -1,224,000 | 670,775,000 | 134,660,000 | 211,494,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$37,493,000
Investing CF
$-1,119,000
Financing CF
$-2,764,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.00
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,725,261,000
Inventory
$158,850,000
Receivables
$111,573,000
ST Investments
$166,867,000
EBIT TTM
$-46,702,000
Pretax Income TTM
$-17,129,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$176,112,000
EBITDA
$-21,986,000
Free Cash Flow
$39,855,376
Enterprise Value
$-60,571,076
Total Cash
$323,379,008
Total Debt
$7,611,000
Shares Out
42,042,348
Trailing EPS
$-0.80
Book Value
$21.08
ROE
-4.2%
ROA
-2.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 213,646,000 | -13,941,000 | -38,798,000 | 670,775,000 | 211,494,000 | 459,281,000 | 6,728,000 |
| Dec 2024 | 228,614,000 | -91,797,000 | -82,183,000 | 685,349,000 | 199,173,000 | 486,176,000 | -31,020,000 |
| Dec 2023 | 306,911,000 | -56,616,000 | -59,112,000 | 831,684,000 | 279,587,000 | 552,097,000 | 6,880,000 |
| Dec 2022 | 369,193,000 | -92,343,000 | -105,803,000 | 886,179,000 | 290,846,000 | 595,333,000 | -180,092,000 |
TTM Snapshot
Revenues TTM
$186,231,000
NetIncome TTM
$-27,124,000
OpCashFlow TTM
—
Assets (Latest)
$624,363,000
Forward EPS
$0.98
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KMDA | KAMADA LTD | $470.92M | $8.16 | — |
| NGNE | Neurogene Inc. | $478.19M | $23.10 | — |
| STTK | Shattuck Labs, Inc. | $467.46M | $4.59 | — |
| IMMP | IMMUTEP Ltd | $480.43M | $3.26 | — |
| BLSM | BlossomHill Therapeutics, Inc. | $480.91M | $15.13 | — |
News headlines (Yahoo Finance, 1h cache)
Amarin: 3 Key Takeaways for Long-Term Investors
2026-11-11 22:35 · Yahoo
Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026
2026-11-09 13:00 · Yahoo
Amarin (AMRN) Q3 Results Recast Profit Story As Revenue Falls
2026-10-30 01:14 · Yahoo
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
2026-10-29 15:31 · Yahoo
Amarin: Q3 Earnings Snapshot
2026-10-28 18:36 · Yahoo
Amarin (AMRN) Q3 2026 Earnings Call Transcript
2026-10-28 16:42 · Yahoo
Amarin Returns to Quarterly Profit as Cost Reductions Offset 20% Revenue Decline
2026-10-28 16:02 · Yahoo
What Amarin (AMRN) Said on Its Q3 Earnings Call
2026-10-28 14:04 · Yahoo
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
2026-10-28 11:00 · Yahoo
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patien
2026-10-25 12:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.